Joanna Sadowska, PhD, EMBA

🔝 𝐓𝐡𝐞 𝐭𝐨𝐩 10 𝐩𝐡𝐚𝐫𝐦𝐚 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐛𝐲 𝐦𝐚𝐫𝐤𝐞𝐭 𝐜𝐚𝐩

The market cap of the top 10 pharma companies has increased from over $1090B USD to over $3300B, tripling its value.

Here are the top 10 pharma companies in 2024 by market cap:

1. 𝐄𝐥𝐢 𝐋𝐢𝐥𝐥𝐲 𝐚𝐧𝐝 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 - $695.23B
2. 𝐍𝐨𝐯𝐨 𝐍𝐨𝐫𝐝𝐢𝐬𝐤 - $540.05B
3. 𝐉𝐨𝐡𝐧𝐬𝐨𝐧 & 𝐉𝐨𝐡𝐧𝐬𝐨𝐧 - $382.51B
4. 𝐀𝐛𝐛𝐕𝐢𝐞 - $331.2B
5. 𝐌𝐞𝐫𝐜𝐤 - $285.14B
6. 𝐑𝐨𝐜𝐡𝐞 - $257.4B
7. 𝐀𝐬𝐭𝐫𝐚𝐙𝐞𝐧𝐞𝐜𝐚 - $249.96B
8. 𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬 - $229.63B
9. 𝐀𝐦𝐠𝐞𝐧 - $167.91B
10. 𝐏𝐟𝐢𝐳𝐞𝐫- $163.48B

Market demand for GLP-1 agonists placed Eli Lilly and Novo Nordisk at the top.

𝘚𝘩𝘰𝘶𝘭𝘥 𝘸𝘦 𝘦𝘹𝘱𝘦𝘤𝘵 𝘢𝘯𝘺 𝘤𝘩𝘢𝘯𝘨𝘦𝘴 𝘪𝘯 2024 𝘰𝘳 𝘳𝘢𝘵𝘩𝘦𝘳 𝘢 𝘨𝘳𝘰𝘸𝘵𝘩 𝘰𝘧 𝘵𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘢𝘳𝘦𝘢𝘴 𝘧𝘰𝘳 𝘰𝘣𝘦𝘴𝘪𝘵𝘺 𝘢𝘯𝘥 𝘥𝘪𝘢𝘣𝘦𝘵𝘦𝘴?

Source: https://lnkd.in/dm7afTvx

#marketcap #pharma #biotech #data #drjojo

*Data does not include pharma companies which have been acquired during this time.

💸 𝐖𝐡𝐢𝐜𝐡 𝐝𝐫𝐮𝐠𝐬 𝐰𝐢𝐥𝐥 𝐥𝐨𝐬𝐞 𝐩𝐚𝐭𝐞𝐧𝐭𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐦𝐢𝐧𝐠 𝐲𝐞𝐚𝐫𝐬?

⚆ Nearly 200 drugs are going off-patent in the near future
⚆ These include at least 69 blockbusters (>$1B in annual sales)
⚆ This could lead to over 49% revenue decline for major companies

The pharmaceutical industry is staring down a major patent cliff, with more than $300B in sales at risk in coming years.

Unlike the previous patent cliff, this one includes a fair number of biologics, making the transition to biosimilars highly relevant.

Navigating this coming cliff will require a combination of innovation and strategy from the pharmaceutical industry.

𝘞𝘩𝘰 𝘸𝘪𝘭𝘭 𝘣𝘦 𝘵𝘩𝘦 𝘣𝘪𝘨𝘨𝘦𝘴𝘵 𝘭𝘰𝘴𝘦𝘳 𝘪𝘯 𝘵𝘩𝘦 𝘤𝘰𝘮𝘪𝘯𝘨 𝘺𝘦𝘢𝘳𝘴?

Check the graphic and comment.

*The infographic represents US patent expiry and is not exhaustive of all off-patents.

#pharma #biotech #drjojo

Sources: PharmaVoice, BioSpace, Statista

🔬 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐂𝐑𝐎𝐬 𝐛𝐚𝐬𝐞𝐝 𝐨𝐧 2023 𝐫𝐞𝐯𝐞𝐧𝐮𝐞

Contract Research Organisations (CROs) are a significant part of the pharma, biotech, and medical device ecosystem, and their revenue is expected to grow, reaching USD 104.60 billion by 2033.

Who are the biggest players globally?

Here are the top CROs based on 2023 revenue (in million US dollars):

1. 𝐓𝐡𝐞𝐫𝐦𝐨 𝐅𝐢𝐬𝐡𝐞𝐫 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜* - $23,041M
2. 𝐈𝐐𝐕𝐈𝐀 (𝐐𝐮𝐢𝐧𝐭𝐢𝐥𝐞𝐬𝐈𝐌𝐒 𝐇𝐨𝐥𝐝𝐢𝐧𝐠𝐬) - $14,984M
3. 𝐋𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐲 𝐂𝐨𝐫𝐩. 𝐨𝐟 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐇𝐨𝐥𝐝𝐢𝐧𝐠𝐬 (𝐢𝐧𝐜𝐥. 𝐂𝐨𝐯𝐚𝐧𝐜𝐞) - $12,162M
4. 𝐈𝐜𝐨𝐧 𝐏𝐮𝐛𝐥𝐢𝐜 𝐋𝐢𝐦𝐢𝐭𝐞𝐝 𝐂𝐨𝐫𝐩. - $8,120M
5. 𝐖𝐮𝐗𝐢 𝐀𝐩𝐩𝐭𝐞𝐜** - $5,658M
6. 𝐒𝐲𝐧𝐞𝐨𝐬 𝐇𝐞𝐚𝐥𝐭𝐡 (2022)*** - $5,393M
7. 𝐂𝐡𝐚𝐫𝐥𝐞𝐬 𝐑𝐢𝐯𝐞𝐫 𝐋𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐢𝐞𝐬 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥, 𝐈𝐧𝐜. - $4,129M
8. 𝐏𝐚𝐫𝐞𝐱𝐞𝐥 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐫𝐩. - $3,800M
9. 𝐌𝐞𝐝𝐩𝐚𝐜𝐞 𝐇𝐨𝐥𝐝𝐢𝐧𝐠𝐬, 𝐈𝐧𝐜. - $1,886M

𝘚𝘩𝘰𝘶𝘭𝘥 𝘸𝘦 𝘦𝘹𝘱𝘦𝘤𝘵 𝘵𝘩𝘢𝘵 𝘱𝘩𝘢𝘳𝘮𝘢 𝘢𝘯𝘥 𝘣𝘪𝘰𝘵𝘦𝘤𝘩 𝘸𝘪𝘭𝘭 𝘭𝘦𝘷𝘦𝘳𝘢𝘨𝘦 𝘮𝘰𝘳𝘦 𝘊𝘙𝘖𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘤𝘰𝘮𝘪𝘯𝘨 𝘺𝘦𝘢𝘳𝘴?

#cro #pharma #biotech #clinicaldevelopment #drjojo

Source: Statista

*Only Laboratory Products & Biopharma
Services segment. No separate information about pure clinical research-related revenues. **Estimated. ***Went private during 2023, thus no data available.